Chengdu Kanghong Pharmaceuticals Group Co Ltd (SHE:002773) — Market Cap & Net Worth
Market Cap & Net Worth: Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773)
Chengdu Kanghong Pharmaceuticals Group Co Ltd (SHE:002773) has a market capitalization of $2.92 Billion (CN¥19.97 Billion) as of August 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #4933 globally and #820 in its home market, demonstrating a 3.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Kanghong Pharmaceuticals Group Co Ltd's stock price CN¥21.68 by its total outstanding shares 921326354 (921.33 Million). See Chengdu Kanghong Pharmaceuticals Group C (002773) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Market Cap History: 2015 to 2026
Chengdu Kanghong Pharmaceuticals Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $5.36 Billion to $2.92 Billion (-3.70% CAGR).
Chengdu Kanghong Pharmaceuticals Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.88x
Chengdu Kanghong Pharmaceuticals Group Co Ltd's market cap is 0.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.47x
Chengdu Kanghong Pharmaceuticals Group Co Ltd's market cap is 3.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.57 Billion | $2.54 Billion | $496.75 Million | 2.19x | 11.20x |
| 2017 | $6.06 Billion | $2.79 Billion | $644.20 Million | 2.18x | 9.41x |
| 2018 | $3.37 Billion | $2.92 Billion | $694.94 Million | 1.15x | 4.85x |
| 2019 | $4.78 Billion | $3.26 Billion | $718.19 Million | 1.47x | 6.65x |
| 2020 | $6.27 Billion | $3.30 Billion | -$269.85 Million | 1.90x | N/A |
| 2021 | $2.66 Billion | $3.61 Billion | $421.08 Million | 0.74x | 6.32x |
| 2022 | $2.07 Billion | $3.39 Billion | $896.67 Million | 0.61x | 2.30x |
| 2023 | $2.44 Billion | $3.96 Billion | $1.04 Billion | 0.62x | 2.34x |
| 2024 | $2.64 Billion | $4.45 Billion | $1.19 Billion | 0.59x | 2.22x |
| 2025 | $4.04 Billion | $4.59 Billion | $1.16 Billion | 0.88x | 3.47x |
Competitor Companies of 002773 by Market Capitalization
Companies near Chengdu Kanghong Pharmaceuticals Group Co Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Chengdu Kanghong Pharmaceuticals Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Chengdu Kanghong Pharmaceuticals Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Chengdu Kanghong Pharmaceuticals Group Co Ltd's market cap moved from $5.36 Billion to $ 2.92 Billion, with a yearly change of -3.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.92 Billion | -27.66% |
| 2025 | CN¥4.04 Billion | +52.91% |
| 2024 | CN¥2.64 Billion | +8.09% |
| 2023 | CN¥2.44 Billion | +18.38% |
| 2022 | CN¥2.07 Billion | -22.36% |
| 2021 | CN¥2.66 Billion | -57.55% |
| 2020 | CN¥6.27 Billion | +31.13% |
| 2019 | CN¥4.78 Billion | +41.92% |
| 2018 | CN¥3.37 Billion | -44.48% |
| 2017 | CN¥6.06 Billion | +8.97% |
| 2016 | CN¥5.57 Billion | +3.92% |
| 2015 | CN¥5.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Chengdu Kanghong Pharmaceuticals Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.92 Billion USD |
| MoneyControl | $2.92 Billion USD |
| MarketWatch | $2.92 Billion USD |
| marketcap.company | $2.92 Billion USD |
| Reuters | $2.92 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.